Trial Profile
A Phase II Study of Concurrent Chemoradiation Plus Durvalumab (MEDI4736) Followed by Surgery Followed by Adjuvant Durvalumab (MEDI4736) in Medically Operable Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Oct 2023 Status changed from active, no longer recruiting to discontinued (Investigator decided to halt study due to low accrual).
- 08 Dec 2022 Planned End Date changed from 1 Oct 2023 to 1 Nov 2023.
- 22 Jul 2022 Planned End Date changed from 1 Apr 2023 to 1 Oct 2023.